Best Mart 360 introduces China Merchants Hoi Tung as major shareholder, with the acquisition of 49% of the company’s shares at HK$1.76 per share
HONG KONG SAR - Media OutReach - 27 March 2023 - Best Mart 360 Holdings…
3 years ago
United in Purpose: CSG Launches Inaugural Impact Report
Company shares commitment to long-term strategy and progress in 2022 on social impact and sustainability…
3 years ago
Cyara Acquires Spearline to Deliver World’s Most Comprehensive Customer Experience Assurance Platform
Strategic acquisition expands Cyara’s solutions for AI and cloud contact center migration assurance REDWOOD CITY,…
3 years ago
Uni-Bio Science Group Limited Announces 2022 Annual Results
Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New…
3 years ago
New Global Refinery Capacity Caters to High-Demand Hotspots, an Industrial Info News Alert
SUGAR LAND, Texas--(BUSINESS WIRE)--Researched by Industrial Info Resources -- Around the world, large-scale refineries are…
3 years ago
New Global Refinery Capacity Caters to High-Demand Hotspots, an Industrial Info News Alert
SUGAR LAND, Texas--(BUSINESS WIRE)--Researched by Industrial Info Resources -- Around the world, large-scale refineries are…
3 years ago
L’Officiel Inc. SAS Granted Permits by the Ministry of Home Affairs of Malaysia to Publish Locally and Achieved Another Milestone Under the Direct Owner’s Model
NEW YORK & HONG KONG & SINGAPORE--(BUSINESS WIRE)--L’Officiel Inc. SAS (“L’Officiel”), a subsidiary of AMTD…
3 years ago
L’Officiel Inc. SAS Granted Permits by the Ministry of Home Affairs of Malaysia to Publish Locally and Achieved Another Milestone Under the Direct Owner’s Model
NEW YORK & HONG KONG & SINGAPORE--(BUSINESS WIRE)--L’Officiel Inc. SAS (“L’Officiel”), a subsidiary of AMTD…
3 years ago
OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
SUWON, South Korea--(BUSINESS WIRE)--#AMD--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today…
3 years ago
OliX Pharmaceuticals Doses First Patient in Clinical Trial for RNAi Therapeutic OLX10212 for Dry and Wet Age-related Macular Degeneration
SUWON, South Korea--(BUSINESS WIRE)--#AMD--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today…
3 years ago